×
BeiGene Total Assets 2014-2024 | ONC
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
BeiGene total assets for the quarter ending September 30, 2024 were
$5.831B
, a
5.54% increase
year-over-year.
BeiGene total assets for 2023 were
$5.805B
, a
9% decline
from 2022.
BeiGene total assets for 2022 were
$6.379B
, a
25.26% decline
from 2021.
BeiGene total assets for 2021 were
$8.536B
, a
52.4% increase
from 2020.
View More
BeiGene Total Assets 2014-2024 | ONC
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
BeiGene total assets for 2023 were
$5.805B
, a
9% decline
from 2022.
BeiGene total assets for 2022 were
$6.379B
, a
25.26% decline
from 2021.
BeiGene total assets for 2021 were
$8.536B
, a
52.4% increase
from 2020.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$139.4B
Bristol Myers Squibb (BMY)
$115.2B
Gilead Sciences (GILD)
$114.5B
Vertex Pharmaceuticals (VRTX)
$104.5B
CSL (CSLLY)
$84.4B
Regeneron Pharmaceuticals (REGN)
$78.6B
GSK (GSK)
$70.4B
Argenex SE (ARGX)
$37.4B
Alnylam Pharmaceuticals (ALNY)
$30.1B
BioNTech SE (BNTX)
$27.6B
Biogen (BIIB)
$21.9B
Illumina (ILMN)
$20.8B
Moderna (MRNA)
$16.2B
Genmab (GMAB)
$13.9B
Incyte (INCY)
$13.4B
BioMarin Pharmaceutical (BMRN)
$12.7B
Insmed (INSM)
$12.5B
Sarepta Therapeutics (SRPT)
$11.9B
Bio-Techne Corp (TECH)
$11.4B
Exact Sciences (EXAS)
$10.5B
Vaxcyte (PCVX)
$10.4B
QIAGEN (QGEN)
$10.2B
Swedish Orphan Biovitrum (BIOVF)
$10.1B
Exelixis (EXEL)
$9.7B
Bio-Rad Laboratories (BIO.B)
$9.1B
Intra-Cellular Therapies (ITCI)
$8.9B
Roivant Sciences (ROIV)
$8.8B
Ascendis Pharma (ASND)
$8.4B
Repligen (RGEN)
$8B
Jazz Pharmaceuticals (JAZZ)
$7.5B